Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.

In today’s ACT Brief, we close out our McKinsey interview series with a look at how AI could transform clinical trials end to ...

The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Empowering resilience in Mozambique under the America First Global Health Strategy Press Statement Thomas "Tommy" Pigott, Principal Deputy Spokesperson at the U ...

Zimbabwe is preparing to place at least 46 500 people on a long-acting HIV prevention drug early next year marking the country's first rollout of Lenacapavir a twice-yearly injectable that offers ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

Gilead has already had success with the single-pill combination therapy in the ARTISTRY-1 trial.

Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...